Introduction {#sec1-0300060518798507}
============

Lung cancer results from the uncontrolled growth of lung tissue cells, which may also cause metastasis.^[@bibr1-0300060518798507]^ Lung cancer is the leading cause of cancer-related death, both in China and worldwide, with 1- and 5-year survival rates of only 42% and 15%, respectively.^[@bibr2-0300060518798507]^ Lung cancer is reportedly the most common cancer among men and women, representing huge social and economic burdens in both developed and developing countries.^[@bibr3-0300060518798507]^ Although antioxidant vitamins and photochemicals have shown protective trends, the roles of trace metals in lung cancer risk remain poorly studied.^[@bibr4-0300060518798507],[@bibr5-0300060518798507]^

Copper is an essential trace metal that plays a key role in maintaining DNA integrity through avoiding oxidative DNA damage or affecting gene mutations.^[@bibr6-0300060518798507],[@bibr7-0300060518798507]^ However, although some studies have reported higher serum copper levels in patients with lung cancer compared with controls,^[@bibr8-0300060518798507][@bibr9-0300060518798507]--[@bibr10-0300060518798507]^ others found no significant association^[@bibr11-0300060518798507],[@bibr12-0300060518798507]^ or indeed a converse association.^[@bibr13-0300060518798507]^ The effect of serum copper levels on lung cancer risk thus remains controversial. We conducted a meta-analysis to determine the relationship between serum copper levels and lung cancer, and evaluated potential heterogeneities among previous studies.

Methods {#sec2-0300060518798507}
=======

Study selection {#sec3-0300060518798507}
---------------

We performed a comprehensive search of the literature for studies examining serum copper levels and lung cancer up to April 1st, 2018. The PubMed, WanFang, CNKI, and SinoMed databases were searched using the terms "copper concentration" or "copper levels" or "copper" or "Cu" or "trace element" in combination with "lung cancer" or "lung tumor". Furthermore, references in the relevant articles were also searched to identify other eligible articles.

Inclusion and exclusion criteria {#sec4-0300060518798507}
--------------------------------

Two investigators (XPZ and QY) independently searched and reviewed articles for eligibility using the following inclusion criteria: 1) studies focusing on patients with lung cancer; 2) observational studies; 3) numbers, mean and standard deviation of serum copper levels for cases and controls available; 4) studies on humans; and 5) studies published in English or Chinese.

Data extraction {#sec5-0300060518798507}
---------------

Two of the authors (XPZ and QY) independently extracted the following data from the included studies and recorded it in a spreadsheet: 1) first author's name; 2) publication year; 3) study design; 4) country; 5) number of cases and controls; 6) sex of cases; 7) age; 8) mean and standard deviation of serum copper levels in cases and control; and 9) serum determination method. Other relevant data were also extracted from individual studies.

Statistical analysis {#sec6-0300060518798507}
--------------------

The meta-analysis was carried out using Stata 12.0 software (StataCorp, College Station, TX, USA). Continuous outcomes between serum copper levels and lung cancer were evaluated by calculating the standard mean deviation (SMD) and 95% confidence interval (CI).^[@bibr14-0300060518798507]^ We performed meta-analyses on the identified studies overall and also carried out a subanalysis according to geographic location. The copper concentration in the serum was converted into µmol/L for all studies. Statistical heterogeneity was assessed based on Q and *I*^2^ tests.^[@bibr15-0300060518798507]^ The results were combined using a random-effects model. The high between-study heterogeneity was explored by meta-regression analysis.^[@bibr16-0300060518798507]^ Publication bias was evaluated by visual investigation of Begg's filled funnel plots^[@bibr17-0300060518798507]^ and Egger's regression asymmetry test.^[@bibr18-0300060518798507]^

Results {#sec7-0300060518798507}
=======

Search results and characteristics {#sec8-0300060518798507}
----------------------------------

The initial screening identified 87, 20, 87, and 79 articles from the PubMed, WanFang, CNKI, and SinoMed databases, respectively. Two additional records were identified through other sources. [Figure 1](#fig1-0300060518798507){ref-type="fig"} shows a flow diagram of the study. A total of 33 articles^[@bibr8-0300060518798507][@bibr9-0300060518798507][@bibr10-0300060518798507][@bibr11-0300060518798507][@bibr12-0300060518798507]--[@bibr13-0300060518798507],[@bibr19-0300060518798507][@bibr20-0300060518798507][@bibr21-0300060518798507][@bibr22-0300060518798507][@bibr23-0300060518798507][@bibr24-0300060518798507][@bibr25-0300060518798507][@bibr26-0300060518798507][@bibr27-0300060518798507][@bibr28-0300060518798507][@bibr29-0300060518798507][@bibr30-0300060518798507][@bibr31-0300060518798507][@bibr32-0300060518798507][@bibr33-0300060518798507][@bibr34-0300060518798507][@bibr35-0300060518798507][@bibr36-0300060518798507][@bibr37-0300060518798507][@bibr38-0300060518798507][@bibr39-0300060518798507][@bibr40-0300060518798507][@bibr41-0300060518798507][@bibr42-0300060518798507][@bibr43-0300060518798507][@bibr44-0300060518798507]--[@bibr45-0300060518798507]^ involving 3026 lung cancer patients and 9439 controls was finally considered suitable for this study. The characteristics of each study are shown in [Table 1](#table1-0300060518798507){ref-type="table"}.

![Study selection process for this meta-analysis](10.1177_0300060518798507-fig1){#fig1-0300060518798507}

###### 

Characteristics of all included studies

![](10.1177_0300060518798507-table1)

  Study, year \[ref\]            Country   Age (year) (range or mean ± SD)   Study type           Lung cancer cases   Controls   Method of copper measurement                                    
  ------------------------------ --------- --------------------------------- -------------------- ------------------- ---------- ------------------------------ ------ ------------------------- -----------------------------------------------------------
  Sun et al. 1991 \[8\]          China     30--75                            Case-control         91                  0.00       1.267 ± 0.278 (µg/mL)          138    0.921 ± 0.198 (µg/mL)     AAS (IL-951, USA)
  Sun et al. 1991 \[8\]          China     30--75                            Case-control         13                  100.00     1.468 ± 0.416 (µg/mL)          114    1.111 ± 0.324 (µg/mL)     AAS (IL-951, USA)
  Cobanoglu et al. 2010 \[13\]   Turkey    54 ± 8.29                         Case-control         30                  33.33      0.977 ± 0.316 (µg/dL)          20     1.748 ± 0.198 (µg/dL)     UNICAM-929 spectrophotometer (Unicam Ltd., Cambridge, UK)
  Diez et al. 1989 \[19\]        Spain     60 ± 7                            Case-control         64                  7.81       1.4 ± 0.316 (µg/mL)            100    1 ± 0.182 (µg/mL)         AAS (Perkin-Elmer 5.000)
  Huhti et al. 1980 \[20\]       Finland   37--80                            Case-control         149                 5.37       1.42 ± 0.3 (mg/L)              19     1.03 ± 0.26 (mg/L)        AAS (Perkin-Elmer Model 303)
  Jin et al. 2011 \[9\]          China     34.9 ± 21.3                       Case-control         154                 10.39      1.624 ± 0.818 (µg/mL)          154    1.285 ± 0.524 (µg/mL)     AAS (Wako Pure Chemical Industries, Osaka, Japan)
  Oyama et al. 1994 \[21\]       Japan     26--83                            Case-control         109                 34.86      122.9 ± 3.77 (µg/dL)           53     109.5 ± 5.39 (µg/dL)      AAS (Wako Pure Chemical Industries, Osaka, Japan)
  Zowczak et al. 2001 \[22\]     Poland    42--87                            Case-control         14                  14.29      22.9 ± 6.2 (µmol/L)            18     15 ± 1.5 (µmol/L)         Flame AAS (Perkin Elmer)
  Feng et al. 2006 \[23\]        China     18--82                            Observation trials   13                  NA         19 ± 2.36 (µmol/L)             36     14.92 ± 2.71 (µmol/L)     Flame AAS
  Zhang et al. 1997 \[24\]       China     25--80                            Case-control         64                  40.63      1.512 ± 0.374 (mg/L)           31     1.061 ± 0.157 (mg/L)      AAS
  Jin et al. 2001 \[25\]         China     45--70                            Case-control         40                  7.50       21.7 ± 6.55 (µmol/L)           46     17.2 ± 2.48 (µmol/L)      AAS
  Zhang et al. 1994 \[26\]       China     59 ± 9                            Case-control         40                  10.00      29.67 ± 5.34 (µmol/L)          24     18.84 ± 2.98 (µmol/L)     AAS
  Xu et al. 1993 \[11\]          China     56 ± 7.5                          Case-control         42                  9.52       19.14 ± 4.29 (µmol/L)          40     19.61 ± 1.88 (µmol/L)     AAS
  Zhou et al. 1995 \[27\]        China     39--69                            Case-control         186                 31.18      1.481 ± 0.163 (µg/mL)          150    1.035 ± 0.094 (µg/mL)     AAS
  Chen et al. 1994 \[28\]        China     37--72                            Case-control         58                  25.86      20.1 ± 5.6 (mol/L)             100    18.5 ± 5.1 (mol/L)        AAS (MFX-ID)
  Luo et al. 1996 \[29\]         China     40--70                            Case-control         35                  NA         17.94 ± 4.09 (µmol/L)          22     9.76 ± 1.89 (µmol/L)      AAS
  Mo et al. 1995 \[30\]          China     58.5                              Case-control         57                  21.05      153.44 ± 33.38 (µg/dL)         46     93.77 ± 12.86 (µg/dL)     AAS
  He et al. 1995 \[31\]          China     34--72                            Case-control         143                 39.16      24.194 ± 9.135 (µmol/L)        50     17.402 ± 5.264 (µmol/L)   AAS
  Wei et al. 2002 \[32\]         China     22--76                            Case-control         79                  41.77      1.093 ± 0.073 (µg/mL)          32     0.867 ± 0.039 (µg/mL)     AAS ( p-100, PE Co., USA)
  Huang et al. 1999 \[33\]       China     40--72                            Case-control         27                  14.81      1.341 ± 0.304 (µg/mL)          45     1.084 ± 0.182 (µg/mL)     AAS
  Zhao et al. 1993 \[34\]        China     43--62                            Case-control         46                  13.04      21.36 ± 4.6 (µmol/L)           50     15.76 ± 4.2 (µmol/L)      AAS (BJKP-36, Beijing, China)
  He et al. 2011 \[10\]          China     38--69                            Case-control         104                 29.81      23.15 ± 3.16 (µmol/L)          122    14.52 ± 1.75 (µmol/L)     AAS
  Chen et al. 1998 \[35\]        China     47--72                            Case-control         43                  32.56      19.08 ± 3.41 (µmol/L)          180    13.85 ± 2.36 (µmol/L)     AAS (A670, Shimadzu, Japan)
  Liang et al. 1992 \[36\]       China     61                                Case-control         57                  21.05      28.75 ± 9.7 (µmol/L)           80     19.76 ± 3.56 (µmol/L)     AAS (WFX-ID, China)
  Huang et al. 1998 \[12\]       China     25--65                            Case-control         136                 19.12      21.453 ± 5.783 (µmol/L)        7101   20.713 ± 5.508 (µmol/L)   AAS (AA670/C2H2, Shimadzu)
  Wang et al. 2003 \[37\]        China     28--69                            Case-control         50                  40.00      1.04 ± 0.2 (µg/L)              60     0.77 ± 0.22 (µg/L)        AAS
  Cheng et al. 2011 \[38\]       China     37--68                            Case-control         197                 32.99      1.19 ± 0.13 (µmol/L)           93     0.87 ± 0.35 (µmol/L)      AAS
  Xie et al. 2000 \[39\]         China     35--68                            Case-control         64                  45.31      25.3 ± 6.3 (µmol/L)            100    22.1 ± 1.7 (µmol/L)       AAS
  Du et al. 1996 \[40\]          China     22--73                            Case-control         73                  31.51      21.3 ± 4.3 (µmol/L)            63     15.3 ± 3.4 (µmol/L)       AAS
  Zhu et al. 1997 \[41\]         China     NA                                Case-control         56                  NA         21.05 ± 3.56 (µmol/L)          118    16.01 ± 2.13 (µmol/L)     AAS (3030, Perkin Elmer Zeeman, USA)
  Zhang et al. 2000 \[42\]       China     25--77                            Case-control         310                 17.74      1.151 ± 0.264 (µg/mL)          48     1.068 ± 0.233 (µg/mL)     AAS (180-80, Shimadzu, Japan)
  Hu et al. 2000 \[43\]          China     36--77                            Case-control         56                  17.86      1.508 ± 0.379 (µg/mL)          60     1.403 ± 0.148 (µg/mL)     AAS
  Guo et al. 1994 \[44\]         China     55.1                              Case-control         26                  26.92      2.81 ± 1.54 (µg/mL)            26     0.82 ± 0.21 (µg/mL)       AAS (AA-40p, Varian, USA)
  Han et al. 1999 \[45\]         China     NA                                Case-control         400                 NA         1.12 ± 0.43 (µg/mL)            100    0.87 ± 0.26 (µg/mL)       AAS (3030, PE Co., USA)

AAS, atomic absorption spectrophotometry; SD, standard deviation; NA, not available

Serum copper levels and risk of lung cancer {#sec9-0300060518798507}
-------------------------------------------

In the overall analysis, lung cancer patients had significantly higher serum copper levels than controls (summary SMD=1.103, 95%CI=1.040--1.165, Z=34.55, *P* for Z test \<0.001), with significant between-study heterogeneity (*I*^2^=96.4%, *P*\<0.001) ([Figure 2](#fig2-0300060518798507){ref-type="fig"}).

![Forest plot of the association between serum copper levels and lung cancer risk. SMD, standard mean error; CI, confidence interval](10.1177_0300060518798507-fig2){#fig2-0300060518798507}

Thirty-two of the included 33 articles were case-control studies, and the result for these was consistent with the overall result (summary SMD=1.099, 95%CI=1.036--1.162, Z=34.30, *P* for Z test \<0.001). In a stratified analysis according to geographic location, the associations between serum copper levels and lung cancer were significant for both Asian (summary SMD=1.078, 95%CI=1.013--1.142, Z=32.88, *P* for Z test \<0.001\] and European populations (summary SMD=1.568, 95%CI=1.292--1.845, Z=11.13, *P* for Z test \<0.001). Detailed results are shown in [Table 2](#table2-0300060518798507){ref-type="table"}.

###### 

Overall and subgroup analyses of relationship between serum copper levels and lung cancer risk

![](10.1177_0300060518798507-table2)

  Study                 No. of studies   SMD (95% CI)           Z test   Heterogeneity test          
  --------------------- ---------------- ---------------------- -------- -------------------- ------ ---------
  All                   33               1.103 (1.040--1.165)   34.55    \<0.001              96.4   \<0.001
  Geographic location                                                                                
   Europe               3                1.568 (1.292--1.845)   11.13    \<0.001              0.0    0.444
   Asia                 30               1.078 (1.013--1.142)   32.88    \<0.001              96.6   \<0.001
  Study type                                                                                         
   Case-control         32               1.099 (1.036--1.162)   34.30    \<0.001              96.5   \<0.001
   Observation trials   1                --                     --       --                   --     --

SMD, standard mean deviation; CI, confidence interval

Between-study heterogeneity {#sec10-0300060518798507}
---------------------------

Significant evidence of between-study heterogeneity was detected when we pooled the overall results. We therefore performed univariate meta-regression analysis to explore the source of the high heterogeneity. No specific covariate (publication year, geographic location, case number) accounted for this high heterogeneity.

Publication bias and sensitivity analysis {#sec11-0300060518798507}
-----------------------------------------

Egger's regression asymmetry test (*P*=0.103) and Begg's filled funnel plots ([Figure 3](#fig3-0300060518798507){ref-type="fig"}) detected no publication bias.

![Filled funnel plots of the association between serum copper levels and lung cancer risk. Open circles represent studies included in this meta-analysis, circles in squares represent missing studies. s.e., standard error](10.1177_0300060518798507-fig3){#fig3-0300060518798507}

Sensitivity analysis showed no apparent effect on the overall merged SMD after deleting any individual study, indicating that no single study influenced the overall effect ([Figure 4](#fig4-0300060518798507){ref-type="fig"}).

![Sensitivity analysis of the association between serum copper levels and lung cancer risk. CI, confidence interval. Meta-analysis results with the indicated study omitted](10.1177_0300060518798507-fig4){#fig4-0300060518798507}

Discussion {#sec12-0300060518798507}
==========

Previous analyses have shown inconsistent results regarding the relationship between serum copper levels and lung cancer, probably due to limited sample sizes. We therefore conducted a meta-analysis of pooled data to obtain a comprehensive result and showed that elevated serum copper levels may increase the risk of lung cancer. Furthermore, serum copper levels were higher in lung cancer patients than in controls in both European and Asian populations.

A previous meta-analysis suggested that patients with thyroid cancer had higher copper levels than healthy controls.^[@bibr46-0300060518798507]^ Another meta-analysis showed that serum copper levels were markedly higher in patients with bladder cancer compared with individuals without bladder cancer.^[@bibr47-0300060518798507]^ Furthermore, a recent study found higher serum copper levels in patients with cervical cancer than in controls.^[@bibr48-0300060518798507]^ The current results are consistent with the above studies. The reason why serum copper levels may be elevated in patients with lung cancer may be related to copper metabolism. Serum copper levels in healthy people are associated with ceruloplasmin,^[@bibr49-0300060518798507]^ which is normally catabolized in the liver following cleavage of its terminal sialic acid chains by neuraminidase.^[@bibr50-0300060518798507]^ It has been suggested^[@bibr51-0300060518798507]^ that ceruloplasmin may be resialylated at the tumor cell surface or in the peripheral blood in patients with neoplasms, thus inhibiting its catabolism and potentially explaining the increase in serum copper levels in patients with malignant tumors.

This meta-analysis had several important strengths. First, the study included a large numbers of cases and participants, yielding a comprehensive result. Second, removing each individual study from the analysis had no apparent effect on the overall merged SMD, indicating that the results were stable. Third, no small study effect was detected by Egger's regression asymmetry test or Begg's filled funnel plots.

However, several limitations also need to be considered when interpreting the results. First, most of the included studies involved Asian populations and only three studies were from Europe. Although subgroup analysis identified significant associations between serum copper and lung cancer in both these subgroups, future studies in European and other populations are warranted to clarify the relationship between serum copper levels and lung cancer risk. Second, lung cancer is a complex disease with a variety of etiologic factors, including environmental and genetic factors. It is therefore possible that other factors may have influenced the results. Third, although most of the included studies measured copper levels using atomic absorption spectrophotometry, the use of instruments produced by different companies could have led to inconsistent measurements. Finally, significant heterogeneity between studies was observed in this meta-analysis. However, the heterogeneity was mainly related to the strength of the association rather than the direction of the risk estimate, suggesting that the findings in relation to the investigated outcome were promising. Furthermore, an investigation of potential covariates by meta-regression analysis found no significant contribution of publication year, geographic location, sex, or case number to the high between-study heterogeneity. No single study accounted for the significant between-study heterogeneity or influenced the overall result according to sensitivity analysis.

Conclusions {#sec13-0300060518798507}
===========

This meta-analysis concluded that serum copper levels tend to be higher in patients with lung cancer than in controls without lung cancer. Environmental copper exposure may thus increase the risk of lung cancer.
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